Andrew John Armstrong, MD

Associate Professor of Medicine
Associate Professor in Pharmacology and Cancer Biology
Associate Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-8797
Email address andrew.armstrong@duke.edu

1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. PI3 kinase/mTOR inhibition in prostate cancer: mechanisms of sensitivity and resistance
7. Developing prognostic models for progression and survival in metastatic prostate cancer
8. Examining surrogate markers of mortality in metastatic prostate cancer
9. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition

In Their Words

Education and Training

  • Fellowship, Division Of Oncology/Hematology, Johns Hopkins University School of Medicine, 2003 - 2006
  • Internship/Residency, General Internal Medicine, University of Pennsylvania School of Medicine, 2000 - 2003
  • M.Sc., Johns Hopkins University, 2008
  • M.D., University of Virginia School of Medicine, 2000
  • B.S.E., Duke University, 1996

Grants

Publications

McNamara, M, Sweeney, C, Antonarakis, ES, and Armstrong, AJ. "The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation." Prostate Cancer and Prostatic Diseases 21, no. 3 (September 2018): 306-318. (Review)

PMID
29263421
Full Text

Brown, LC, Sonpavde, G, and Armstrong, AJ. "Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?." Prostate Cancer and Prostatic Diseases 21, no. 3 (September 2018): 419-430.

PMID
29858595
Full Text

Wu, M, Huang, P-H, Zhang, R, Mao, Z, Chen, C, Kemeny, G, Li, P, Lee, AV, Gyanchandani, R, Armstrong, AJ, Dao, M, Suresh, S, and Huang, TJ. "Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation." Small (Weinheim an Der Bergstrasse, Germany) 14, no. 32 (August 2018): e1801131-null.

PMID
29968402
Full Text

Fantony, JJ, Howard, LE, Csizmadi, I, Armstrong, AJ, Lark, AL, Galet, C, Aronson, WJ, and Freedland, SJ. "Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study." Biomarkers in Medicine 12, no. 7 (July 2018): 727-736.

PMID
29902938
Full Text

Armstrong, AJ, Anand, A, Edenbrandt, L, Bondesson, E, Bjartell, A, Widmark, A, Sternberg, CN, Pili, R, Tuvesson, H, Nordle, Ö, Carducci, MA, and Morris, MJ. "Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial." Jama Oncology 4, no. 7 (July 2018): 944-951.

PMID
29799999
Full Text

Rathkopf, DE, Beer, TM, Loriot, Y, Higano, CS, Armstrong, AJ, Sternberg, CN, de Bono, JS, Tombal, B, Parli, T, Bhattacharya, S, Phung, D, Krivoshik, A, Scher, HI, and Morris, MJ. "Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial." Jama Oncology 4, no. 5 (May 2018): 694-701.

PMID
29522174
Full Text

Humeniuk, MS, Gupta, RT, Healy, P, McNamara, M, Ramalingam, S, Harrison, M, George, D, Zhang, T, Wu, Y, and Armstrong, AJ. "Platinum sensitivity in metastatic prostate cancer: does histology matter?." Prostate Cancer and Prostatic Diseases 21, no. 1 (April 2018): 92-99.

PMID
29230006
Full Text

Austin, RG, Huang, TJ, Wu, M, Armstrong, AJ, and Zhang, T. "Clinical utility of non-EpCAM based circulating tumor cell assays." Advanced Drug Delivery Reviews 125 (February 2018): 132-142. (Review)

PMID
29366804
Full Text

Zhu, J, Armstrong, AJ, Friedlander, TW, Kim, W, Pal, SK, George, DJ, and Zhang, T. "Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond." Journal for Immunotherapy of Cancer 6, no. 1 (January 25, 2018): 4-null. (Review)

PMID
29368638
Full Text

Armstrong, AJ, Antonarakis, ES, Taplin, M-E, Kelly, WK, Beltran, H, Fizazi, K, Dahut, WL, Shore, N, Slovin, S, George, D, Carducci, MA, Corn, P, Danila, D, Dreicer, R, Heath, E, Rathkopf, D, Liu, G, Nanus, D, Stein, M, Smith, MR, Sternberg, C, Wilding, G, Nelson, PS, Halabi, S, Kantoff, P, Clarke, NW, Evans, CP, Heidenreich, A, Mottet, N, Gleave, M, Morris, MJ, and Scher, HI. "Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet." Annals of Oncology : Official Journal of the European Society for Medical Oncology 29, no. 1 (January 2018): 23-25.

PMID
29088323
Full Text

Pages